Instrument Inactif

Communiqués Mirati Therapeutics

Actions

MRTX

US60468T1051

Communiqués

11/01/24	Mirati Therapeutics - European Commission Approves KRAZATI as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer with a KRASG12C Mutation	AQ
10/01/24	European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation	PR
10/11/23	Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure	PR
08/11/23	MIRATI THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mirati Therapeutics, Inc. - MRTX	BU
06/11/23	MHRA authorises new treatment for rare lung cancer	AQ
06/11/23	Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updates	PR
06/11/23	Mirati: Q3 Earnings Snapshot	AQ
03/11/23	Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation	PR
02/11/23	Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC	AQ
20/10/23	MRTX Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Mirati Therapeutics, Inc. to Bristol Myers Squibb	AQ
17/10/23	Mirati Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer (NSCLC)	PR
09/10/23	MIRATI THERAPEUTICS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mirati Therapeutics, Inc. - MRTX	BU
09/10/23	Bristol Myers Squibb agrees nearly $6bn oncology merger	AQ
27/09/23	Mirati To Present Updated Clinical Data at ESMO Congress 2023	PR
10/09/23	Mirati Presents Two-Year Follow-Up Data from KRYSTAL-1 Study Demonstrating Durable Response and Long-Term Overall Survival at 2023 World Conference on Lung Cancer	PR
05/09/23	Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)	PR
29/08/23	Mirati Therapeutics to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference	PR
23/08/23	Mirati Therapeutics Announces Departure of Chief Financial Officer Laurie Stelzer	PR
21/08/23	Mirati To Present Pooled Clinical Data from Adagrasib's KRYSTAL-1 Study Demonstrating Overall Survival Results at Two-Years of Follow-Up at 2023 World Conference on Lung Cancer	PR
14/08/23	Mirati Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares	AQ
11/08/23	Mirati Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares	PR
09/08/23	Cancer Discovery Publishes Preclinical and Initial Clinical Data for MRTX1719 to Treat MTAP-Deleted Cancers through Novel Approach to MTA-Cooperative PRMT5 Inhibition	PR
09/08/23	Mirati Therapeutics Announces Pricing of Upsized Public Offering	PR
08/08/23	Mirati: Q2 Earnings Snapshot	AQ
08/08/23	Mirati Therapeutics Announces Proposed Public Offering	PR